Contact
searchSearch
HMP Global
Login

Bladder Cancer Specialty Channel

Bladder Cancer
Specialty Channel
FDA Approval
FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer
09/10/2025
Allison Casey
On Tuesday, September 9, 2025, the FDA approved the use of a gemcitabine intravesical system, TAR-200, for the treatment of patients with Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or...
On Tuesday, September 9, 2025, the FDA approved the use of a gemcitabine intravesical system, TAR-200, for the treatment of patients with Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or...
On Tuesday, September 9, 2025,...
09/10/2025
Oncology
FDA Approval
Intravesical Mitomycin Approved for Low-Grade Non-Muscle Invasive Bladder Cancer
06/12/2025
Allison Casey
The US FDA approved mitomycin intravesical solution for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
The US FDA approved mitomycin intravesical solution for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
The US FDA approved mitomycin...
06/12/2025
Oncology
News
Cabozantinib Plus Atezolizumab for Patients With Advanced Urothelial Carcinoma
05/13/2025
Stephanie Holland
According to results from the phase 1b COSMIC-021 trial, cabozantinib plus atezolizumab demonstrated promising clinical efficacy and safety among patients with inoperable, locally advanced or metastatic urothelial carcinoma.
According to results from the phase 1b COSMIC-021 trial, cabozantinib plus atezolizumab demonstrated promising clinical efficacy and safety among patients with inoperable, locally advanced or metastatic urothelial carcinoma.
According to results from the...
05/13/2025
Oncology
Joseph Jacob, MD
Videos
TAR-200 Monotherapy Demonstrates Durability of Response in BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer
05/09/2025
Joseph Jacob, MD, discusses results from cohort 2 of the ongoing phase 2b SunRISe-1 trial which assessed the durability of response of TAR-200 monotherapy among patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle invasive...
Joseph Jacob, MD, discusses results from cohort 2 of the ongoing phase 2b SunRISe-1 trial which assessed the durability of response of TAR-200 monotherapy among patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle invasive...
Joseph Jacob, MD, discusses...
05/09/2025
Oncology
Felix Guerrero-Ramos, MD, PhD
Conference Coverage
TAR-200 for BCG-Unresponsive, Papillary-Only High-Risk Non-Muscle Invasive Bladder Cancer
04/28/2025
Felix Guerrero-Ramos, MD, PhD
Felix Guerrero-Ramos, MD, PhD discusses first results from cohort 4 of the phase 2b SunRISe-1 trial which assessed TAR-200 monotherapy in patients with BCG-unresponsive, papillary-only high-risk non-muscle invasive bladder cancer.
Felix Guerrero-Ramos, MD, PhD discusses first results from cohort 4 of the phase 2b SunRISe-1 trial which assessed TAR-200 monotherapy in patients with BCG-unresponsive, papillary-only high-risk non-muscle invasive bladder cancer.
Felix Guerrero-Ramos, MD, PhD...
04/28/2025
Oncology
News
Sacituzumab Govitecan Fails to Significantly Improve Survival in Advanced Urothelial Carcinoma
04/17/2025
Stephanie Holland
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis...
04/17/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
Thomas Powles, MBBS, MD
Conference Coverage
Continued Efficacy With Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma
02/18/2025
Thomas Powles, MBBS, MD
Thomas Powles, MD, MBBS, discusses the updated analysis of the EV-302 trial which found that enfortumab vedotin plus pembrolizumab continued to show superior efficacy compared with chemotherapy among patients with locally advanced or...
Thomas Powles, MD, MBBS, discusses the updated analysis of the EV-302 trial which found that enfortumab vedotin plus pembrolizumab continued to show superior efficacy compared with chemotherapy among patients with locally advanced or...
Thomas Powles, MD, MBBS,...
02/18/2025
Oncology
Conference Coverage
Durvalumab Plus Intravesical Chemotherapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
02/13/2025
Allison Casey
According to results from the phase 1/2 ADAPT-BLADDER trial, durvalumab plus intravesical gemcitabine and docetaxel showed promising clinical efficacy with high response rates among patients with BCG-unresponsive non-muscle invasive bladder...
According to results from the phase 1/2 ADAPT-BLADDER trial, durvalumab plus intravesical gemcitabine and docetaxel showed promising clinical efficacy with high response rates among patients with BCG-unresponsive non-muscle invasive bladder...
According to results from the...
02/13/2025
Oncology
News
Enfortumab Vedotin Demonstrates Real-World Efficacy Among Patients With Metastatic Urothelial Carcinoma
12/13/2024
Stephanie Holland
According to results from a retrospective study, single-agent enfortumab vedotin demonstrated real-world efficacy among previously treated patients with metastatic urothelial carcinoma.
According to results from a retrospective study, single-agent enfortumab vedotin demonstrated real-world efficacy among previously treated patients with metastatic urothelial carcinoma.
According to results from a...
12/13/2024
Oncology
News
Optimal Disitamab Vedotin Dose for Patients With Chemotherapy-Refractory Advanced Urothelial Carcinoma
12/13/2024
Stephanie Holland
According to results from the phase 1b/2 RC48-C014 study, the addition of 2 mg/kg of disitamab vedotin to toripalimab is preferable to 1.5 mg/kg among patients with chemotherapy-refractory locally advanced or metastatic urothelial carcinoma.
According to results from the phase 1b/2 RC48-C014 study, the addition of 2 mg/kg of disitamab vedotin to toripalimab is preferable to 1.5 mg/kg among patients with chemotherapy-refractory locally advanced or metastatic urothelial carcinoma.
According to results from the...
12/13/2024
Oncology

News

News
Cabozantinib Plus Atezolizumab for Patients With Advanced Urothelial Carcinoma
05/13/2025
Stephanie Holland
According to results from the phase 1b COSMIC-021 trial, cabozantinib plus atezolizumab demonstrated promising clinical efficacy and safety among patients with inoperable, locally advanced or metastatic urothelial carcinoma.
According to results from the phase 1b COSMIC-021 trial, cabozantinib plus atezolizumab demonstrated promising clinical efficacy and safety among patients with inoperable, locally advanced or metastatic urothelial carcinoma.
According to results from the...
05/13/2025
Oncology
Felix Guerrero-Ramos, MD, PhD
Conference Coverage
TAR-200 for BCG-Unresponsive, Papillary-Only High-Risk Non-Muscle Invasive Bladder Cancer
04/28/2025
Felix Guerrero-Ramos, MD, PhD
Felix Guerrero-Ramos, MD, PhD discusses first results from cohort 4 of the phase 2b SunRISe-1 trial which assessed TAR-200 monotherapy in patients with BCG-unresponsive, papillary-only high-risk non-muscle invasive bladder cancer.
Felix Guerrero-Ramos, MD, PhD discusses first results from cohort 4 of the phase 2b SunRISe-1 trial which assessed TAR-200 monotherapy in patients with BCG-unresponsive, papillary-only high-risk non-muscle invasive bladder cancer.
Felix Guerrero-Ramos, MD, PhD...
04/28/2025
Oncology
News
Sacituzumab Govitecan Fails to Significantly Improve Survival in Advanced Urothelial Carcinoma
04/17/2025
Stephanie Holland
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis...
04/17/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
Thomas Powles, MBBS, MD
Conference Coverage
Continued Efficacy With Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma
02/18/2025
Thomas Powles, MBBS, MD
Thomas Powles, MD, MBBS, discusses the updated analysis of the EV-302 trial which found that enfortumab vedotin plus pembrolizumab continued to show superior efficacy compared with chemotherapy among patients with locally advanced or...
Thomas Powles, MD, MBBS, discusses the updated analysis of the EV-302 trial which found that enfortumab vedotin plus pembrolizumab continued to show superior efficacy compared with chemotherapy among patients with locally advanced or...
Thomas Powles, MD, MBBS,...
02/18/2025
Oncology
Conference Coverage
Durvalumab Plus Intravesical Chemotherapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
02/13/2025
Allison Casey
According to results from the phase 1/2 ADAPT-BLADDER trial, durvalumab plus intravesical gemcitabine and docetaxel showed promising clinical efficacy with high response rates among patients with BCG-unresponsive non-muscle invasive bladder...
According to results from the phase 1/2 ADAPT-BLADDER trial, durvalumab plus intravesical gemcitabine and docetaxel showed promising clinical efficacy with high response rates among patients with BCG-unresponsive non-muscle invasive bladder...
According to results from the...
02/13/2025
Oncology
News
Enfortumab Vedotin Demonstrates Real-World Efficacy Among Patients With Metastatic Urothelial Carcinoma
12/13/2024
Stephanie Holland
According to results from a retrospective study, single-agent enfortumab vedotin demonstrated real-world efficacy among previously treated patients with metastatic urothelial carcinoma.
According to results from a retrospective study, single-agent enfortumab vedotin demonstrated real-world efficacy among previously treated patients with metastatic urothelial carcinoma.
According to results from a...
12/13/2024
Oncology
News
Optimal Disitamab Vedotin Dose for Patients With Chemotherapy-Refractory Advanced Urothelial Carcinoma
12/13/2024
Stephanie Holland
According to results from the phase 1b/2 RC48-C014 study, the addition of 2 mg/kg of disitamab vedotin to toripalimab is preferable to 1.5 mg/kg among patients with chemotherapy-refractory locally advanced or metastatic urothelial carcinoma.
According to results from the phase 1b/2 RC48-C014 study, the addition of 2 mg/kg of disitamab vedotin to toripalimab is preferable to 1.5 mg/kg among patients with chemotherapy-refractory locally advanced or metastatic urothelial carcinoma.
According to results from the...
12/13/2024
Oncology
News
Adjuvant PD-1/-L1 Inhibition Significantly Improves Disease-Free Survival for Muscle-Invasive Urothelial Carcinoma Regardless of PD-L1 Status
12/09/2024
Stephanie Holland
Adjuvant immunotherapy with PD-1/-L1 inhibition significantly improved DFS for patients with MIUC, regardless of PD-L1 status.
Adjuvant immunotherapy with PD-1/-L1 inhibition significantly improved DFS for patients with MIUC, regardless of PD-L1 status.
Adjuvant immunotherapy with...
12/09/2024
Oncology
News
Real-World Efficacy of Enfortumab Vedotin for Patients With Advanced Urothelial Carcinoma
12/04/2024
Stephanie Holland
Results from a retrospective real-world analysis confirmed that enfortumab vedotin is a safe and effective treatment option for patients with locally advanced or metastatic urothelial carcinoma.
Results from a retrospective real-world analysis confirmed that enfortumab vedotin is a safe and effective treatment option for patients with locally advanced or metastatic urothelial carcinoma.
Results from a retrospective...
12/04/2024
Oncology

Interactive Features

Quiz
Enfortumab Vedotin for Patients With Advanced Urothelial Carcinoma
10/19/2023
True or False: According to findings from the phase 3 EV-301 trial, enfortumab vedotin maintained clinically meaningful overall survival benefit at a median follow-up of approximately 2 years, compared with chemotherapy, among patients with...
True or False: According to findings from the phase 3 EV-301 trial, enfortumab vedotin maintained clinically meaningful overall survival benefit at a median follow-up of approximately 2 years, compared with chemotherapy, among patients with...
True or False: According to...
10/19/2023
Oncology
Quiz
NECTIN-4 Expression During Metastatic Spread in Urothelial Carcinoma
02/10/2023
In a study evaluating the changes in membranous NECTIN-4 protein expression among urothelial carcinoma progression, what percentage of cases demonstrated a decrease of NECTIN-4 expression during metastatic spread?
In a study evaluating the changes in membranous NECTIN-4 protein expression among urothelial carcinoma progression, what percentage of cases demonstrated a decrease of NECTIN-4 expression during metastatic spread?
In a study evaluating the...
02/10/2023
Oncology
Quiz
Quiz: Rogaratinib Compared With Standard Chemotherapy for FGFR-Altered Urothelial Carcinoma
12/01/2022
In the open-label, multicenter FORT-1 trial, how did the pan-FGFR inhibitor rogaratinib compare to standard chemotherapy, in terms of efficacy in treating patients with FGFR-altered urothelial carcinoma?
In the open-label, multicenter FORT-1 trial, how did the pan-FGFR inhibitor rogaratinib compare to standard chemotherapy, in terms of efficacy in treating patients with FGFR-altered urothelial carcinoma?
In the open-label, multicenter...
12/01/2022
Oncology
Quiz
Quiz: Following TURBT, which treatment was found to be a safe, effective alternative to BCG for patients with NMIBC?
10/18/2022
Following transurethral resection of bladder tumor, which treatment was found to be an effective and safe alternative to bacillus Calmete-Guérin for patients with non-muscle invasive bladder cancer?
Following transurethral resection of bladder tumor, which treatment was found to be an effective and safe alternative to bacillus Calmete-Guérin for patients with non-muscle invasive bladder cancer?
Following transurethral...
10/18/2022
Oncology
Quiz
Quiz: Radical Cystectomy vs Intravesical Therapy for Non-Muscle Invasive Bladder Cancer
09/02/2022
What was the difference in survival found between patients with non-muscle invasive bladder cancer who underwent radical cystectomy vs those who underwent intravesical therapy, within 12 months of receiving BCG?
What was the difference in survival found between patients with non-muscle invasive bladder cancer who underwent radical cystectomy vs those who underwent intravesical therapy, within 12 months of receiving BCG?
What was the difference in...
09/02/2022
Oncology
Test Your Knowledge
Quiz: Which Phase 2 Trial Led to the Approval of Sacituzumab Govitecan for aUC?
02/20/2022
The approval of sacituzumab govitecan  for patients with advanced urothelial cancer was based on which phase 2 trial?
The approval of sacituzumab govitecan  for patients with advanced urothelial cancer was based on which phase 2 trial?
The approval of sacituzumab...
02/20/2022
Oncology
Quiz
Quiz: Which Immunotherapy Drug Treats Advanced or Metastatic Urothelial Cancer?
07/01/2021
Which immunotherapy drug was recently granted accelerated approval by the FDA to treat adult patients with locally advanced or metastatic urothelial cancer?
Which immunotherapy drug was recently granted accelerated approval by the FDA to treat adult patients with locally advanced or metastatic urothelial cancer?
Which immunotherapy drug was...
07/01/2021
Oncology
Quiz
Quiz: Does Nivolumab Provide the Longest DFS Rate for Urothelial Carcinoma?
07/01/2021
In a recent trial that evaluated various treatments for patients with high-risk muscle-invasive urothelial carcinoma, adjuvant nivolumab provided the longest disease-free survival rate.
In a recent trial that evaluated various treatments for patients with high-risk muscle-invasive urothelial carcinoma, adjuvant nivolumab provided the longest disease-free survival rate.
In a recent trial that evaluated...
07/01/2021
Oncology
Test Your Knowledge
Quiz: Risk of Recurrence and Progression for Patients with NMIBC
02/19/2021
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does...
02/19/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment Received FDA Approval for Metastatic Urothelial Carcinoma?
11/03/2020
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by...
11/03/2020
Oncology

Recent News

News
Cabozantinib Plus Atezolizumab for Patients With Advanced Urothelial Carcinoma
05/13/2025
Stephanie Holland
According to results from the phase 1b COSMIC-021 trial, cabozantinib plus atezolizumab demonstrated promising clinical efficacy and safety among patients with inoperable, locally advanced or metastatic urothelial carcinoma.
According to results from the phase 1b COSMIC-021 trial, cabozantinib plus atezolizumab demonstrated promising clinical efficacy and safety among patients with inoperable, locally advanced or metastatic urothelial carcinoma.
According to results from the...
05/13/2025
Oncology
News
Sacituzumab Govitecan Fails to Significantly Improve Survival in Advanced Urothelial Carcinoma
04/17/2025
Stephanie Holland
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis...
04/17/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
News
Enfortumab Vedotin Demonstrates Real-World Efficacy Among Patients With Metastatic Urothelial Carcinoma
12/13/2024
Stephanie Holland
According to results from a retrospective study, single-agent enfortumab vedotin demonstrated real-world efficacy among previously treated patients with metastatic urothelial carcinoma.
According to results from a retrospective study, single-agent enfortumab vedotin demonstrated real-world efficacy among previously treated patients with metastatic urothelial carcinoma.
According to results from a...
12/13/2024
Oncology
News
Optimal Disitamab Vedotin Dose for Patients With Chemotherapy-Refractory Advanced Urothelial Carcinoma
12/13/2024
Stephanie Holland
According to results from the phase 1b/2 RC48-C014 study, the addition of 2 mg/kg of disitamab vedotin to toripalimab is preferable to 1.5 mg/kg among patients with chemotherapy-refractory locally advanced or metastatic urothelial carcinoma.
According to results from the phase 1b/2 RC48-C014 study, the addition of 2 mg/kg of disitamab vedotin to toripalimab is preferable to 1.5 mg/kg among patients with chemotherapy-refractory locally advanced or metastatic urothelial carcinoma.
According to results from the...
12/13/2024
Oncology
News
Adjuvant PD-1/-L1 Inhibition Significantly Improves Disease-Free Survival for Muscle-Invasive Urothelial Carcinoma Regardless of PD-L1 Status
12/09/2024
Stephanie Holland
Adjuvant immunotherapy with PD-1/-L1 inhibition significantly improved DFS for patients with MIUC, regardless of PD-L1 status.
Adjuvant immunotherapy with PD-1/-L1 inhibition significantly improved DFS for patients with MIUC, regardless of PD-L1 status.
Adjuvant immunotherapy with...
12/09/2024
Oncology
News
Real-World Efficacy of Enfortumab Vedotin for Patients With Advanced Urothelial Carcinoma
12/04/2024
Stephanie Holland
Results from a retrospective real-world analysis confirmed that enfortumab vedotin is a safe and effective treatment option for patients with locally advanced or metastatic urothelial carcinoma.
Results from a retrospective real-world analysis confirmed that enfortumab vedotin is a safe and effective treatment option for patients with locally advanced or metastatic urothelial carcinoma.
Results from a retrospective...
12/04/2024
Oncology
News
Pembrolizumab Plus Gemcitabine-Platinum Doublet Chemotherapy Improves Survival Regardless of Platinum Agent for Urothelial Carcinoma
11/19/2024
Stephanie Holland
Subset analysis results from the phase 3 KEYNOTE-361 study demonstrated that the addition of pembrolizumab to gemcitabine-platinum doublet chemotherapy improved survival for patients with advanced or metastatic urothelial carcinoma,...
Subset analysis results from the phase 3 KEYNOTE-361 study demonstrated that the addition of pembrolizumab to gemcitabine-platinum doublet chemotherapy improved survival for patients with advanced or metastatic urothelial carcinoma,...
Subset analysis results from the...
11/19/2024
Oncology
News
UGN-102 Chemoablation as TURBT Alternative for Patients With Recurrent Low-Grade Non-Muscle Invasive Bladder Cancer
11/19/2024
Stephanie Holland
According to results from the phase 3 ENVISION trial, chemoablation with UGN-102 demonstrates clinical promise as an alternative to standard-of-care transurethral resection of the bladder tumor for patients with recurrent low-grade...
According to results from the phase 3 ENVISION trial, chemoablation with UGN-102 demonstrates clinical promise as an alternative to standard-of-care transurethral resection of the bladder tumor for patients with recurrent low-grade...
According to results from the...
11/19/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Stephanie Holland
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use